
Roche Reveals 2 Phase III Trial Results for Vamikibart in Uveitic Macular Edema
Roche Unveils Promising Phase III Data for Vamikibart in Uveitic Macular Edema (UME), Highlighting Potential as First-in-Class Non-Steroidal Treatment Option Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced pivotal Phase III results from two large-scale clinical studies — MEERKAT and…












